Rhode Island College

Digital Commons @ RIC
Master's Theses, Dissertations, Graduate
Research and Major Papers Overview

Master's Theses, Dissertations, Graduate
Research and Major Papers

2017

Ventilator-Associated Pneumonia and the Effectiveness of
Endotracheal Tubes Coated with Silver Sulfadiazine
Nathaniel Van Hueveln

Follow this and additional works at: https://digitalcommons.ric.edu/etd
Part of the Other Nursing Commons

Recommended Citation
Van Hueveln, Nathaniel, "Ventilator-Associated Pneumonia and the Effectiveness of Endotracheal Tubes
Coated with Silver Sulfadiazine" (2017). Master's Theses, Dissertations, Graduate Research and Major
Papers Overview. 251.
https://digitalcommons.ric.edu/etd/251

This Major Paper is brought to you for free and open access by the Master's Theses, Dissertations, Graduate
Research and Major Papers at Digital Commons @ RIC. It has been accepted for inclusion in Master's Theses,
Dissertations, Graduate Research and Major Papers Overview by an authorized administrator of Digital Commons
@ RIC. For more information, please contact digitalcommons@ric.edu.

VENTILATOR-ASSOCIATED PNEUMONIA AND THE EFFECTIVENESS OF
ENDOTRACHEAL TUBES COATED WITH SILVER SULFADIAZINE

by
Nathaniel Van Heuveln
A Major Paper Submitted in Partial Fulfillment
of the Requirements for the Degree of
Master of Science in Nursing
in
The School of Nursing
Rhode Island College
2017

Abstract
Ventilator-associated pneumonia (VAP) is a consequence of intubation and mechanical
ventilation. Bacteria colonize the inner-lumen of endotracheal tubes (ETT) and develop
into a biofilm. One method to reduce/eliminate the develop of biofilms within the ETT is
lining the inner-lumen with silver-sulfadiazine. A systematic review was conducted to
evaluate the effectiveness of silver-coated ETTs for patients that develop VAP. Multiple
databases were searched to identify key literature related to silver-coated ETTs and VAP.
Inclusion and exclusion criteria were identified to finalize the studies that were included
in this systematic review. Five key studies were included in this review. Studies were
further evaluated with PRISMA, a data collection table, the Critical Appraisal Skills
Programme (CASP) and the Critical Appraisal for Summaries of Evidence (CASE)
worksheet. All studies found either a reduction or elimination of bacteria within the ETT,
breathing circuit, or lungs of the study subjects. In addition to the reduced colonization
found across the studies, one study found a reduction in the mortality rate for the
intervention group following a diagnosis of VAP. Certified Registered Nurse
Anesthetists (CRNA) play an important role in educating staff about the impact silvercoated ETTs have on patient outcomes throughout periods of intubation and mechanical
ventilation. Additionally, CRNAs are well positioned to identify patients pre-operatively
that may require prolonged intubation following surgery. By advocating for silver-coated
ETTs for these patients, CRNAs can improve patient outcomes by reducing the
likelihood of these patients developing VAP.
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Ventilator-Associated Pneumonia and the Effectiveness of
Endotracheal Tubes Coated with Silver Sulfadiazine
Background/Statement of the Problem
Ventilator-associated pneumonia (VAP) occurs when patients are mechanically
ventilated and become colonized with bacteria in their endotracheal tube (ETT) that
originates from an external source or gastric content. Miller et al. (2014) defined VAP as
occurring when a patient requiring mechanical ventilation develops a new lower
respiratory infection. Endotracheal tubes increase the risk of developing pneumonia by
suppressing innate protective airway reflexes (Miller et al.). Patients who develop VAP
have increased length of hospitalizations and are intubated for a greater number of days.
Additionally, those who develop VAP have more expensive hospitalizations, require a
greater number of services from the multi-disciplinary hospital care teams and have a
higher mortality rate than patients who do not develop VAP (Mietto, Pinciroli, Patel, &
Berra, 2013). Diagnosis of VAP includes a combination of new or persistent infiltrates
on chest radiography and two of the following: temperature greater than 38.3, blood
leukocytosis (>12 x 109 white blood cells/liter) or purulent tracheal secretions (Hunter,
2012).
The use of silver for treatment of bacterial infections, wounds and injuries is well
established. However, during the past several decades, its’ use has declined due to the
development and availability of antibiotics (Rai, Yadav, & Gade, 2008). As bacteria
become increasingly resistant and harder to treat, silver’s antimicrobial properties have
resurfaced as a viable option for the treatment and prevention of infections throughout the
medical field.
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One of the most frequently implicated sources of VAP are biofilms, which form
on the inner-lumen of the ETT and have unimpeded access to patients’ lungs.
Innovations to the design and composition of ETTs are being studied to determine
efficacy in minimizing the development of VAP and biofilms. Endotracheal tubes that
utilize the impregnation or coating of silver sulfadiazine are designed to reduce the
incidence of VAP by preventing the development of biofilm (Afessa et al., 2010).
Silver ions, with their ability to bind and oxidize Thiol groups and disrupt the
development of respiratory-chain proteins, has been applied to ETTs as a treatment
strategy to prevent bacterial colonization (Pirrone, Pinciroli, & Berra, 2016).
Technological advances in the field of nanomedicine has renewed interest in metal
impregnation, primarily silver, into medical devices (Palanisamy et al., 2014). There is
ongoing research involving the antimicrobial effects of silver on well known bacteria
such as Escherichia coli, Staphylococcus Aureus, and Pseudomonas Aeruginosa. The
relationship between silver and nanomedicine uncovered direct links to the treatment of
bacteria related to the size, shape, and composition of the silver particles’ efficacy of
silver products on specific bacteria (Ge, Li, Wang, Ouyang, Li, & Xing, 2014).
The purpose of this systematic review was to examine the impact of ETTs
impregnated with silver sulfadiazine on patient’s with VAP. The results will be
compared to the incidence of VAP for patients with traditional polyvinyl-chloride ETTs.
Next, the review of the literature will be presented
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Literature Review
The review of literature was performed by accessing the databases Cumulative
Index to Nursing and Allied Health Literature (CINAHL), OVID and PubMed.
Keywords used were ventilator-associated pneumonia, VAP, silver sulfadiazine, ETT,
silver-coated endotracheal tubes and biofilm. Dates searched were between 2006 and
2017.
Incidence and Cost of VAP
The incidence of VAP is estimated to be 1.2%-8.5% per 1,000 ventilator days
with the greatest risk of developing VAP during the first five days of intubation
(Kalanuria, Zai, & Mirski, 2014). Treatment and staffing for VAP are substantial. Shorr,
Zilberberg, & Kollef found that it cost $12,840 for each patient diagnosed with VAP.
Zimlichman et al. suggested the development of VAP, which is the second most
expensive nosocomial infection, cost $40,144 (2013).
Prevention of VAP is a national patient safety standard. The Centers for
Medicare and Medicaid services has proposed non-reimbursement for healthcare centers
where patients are diagnosed with VAP (Mietto, Pinciroli, Patel, & Berra, 2013).
Ventilator-Associated Pneumonia and Intubation
The development of VAP occurs mainly from the ETT obstructing the body from
coughing to protect itself (Kalanuria et al., 2014). The body’s inability to expectorate
potentially infectious pathogens allows them to penetrate deep into the oropharynx.
Ventilator-associated pneumonia is described by Kalanuria et al. as a “complex interplay
between the endotracheal tube, patient risk factors, virulence of invading organisms, and
the host’s immunity” (p. 1). Additional contributing factors include supine positioning,
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enteral feedings through naso/orogastric tubes and trauma (Hunter, 2012). One of the
common sources of bacterial introduction to the lungs occurs during direct laryngoscopy,
which leads to micro-aspiration (Kalanuria et al., 2014).
Following intubation, the cough reflex of the glottis and larynx is inhibited.
Pathogens located within the oral cavity start to adhere to the inner lumen of the standard
polyvinyl chloride (PVC) ETT. When patients remain intubated and ventilated, bacteria
begin to form a microfilm within the ETT which ultimately develops into an endoluminal
biofilm. These pathogens, some of which can lead to VAP, migrate to the lower
respiratory tract (Pirrone et al., 2016).
Following cuff inflation of the ETT, secretions begin to pool in the subglottic area
surrounding the cuff and ultimately seep into the lungs (Kalanuria et al., 2014). The
secretions constantly ooze around the cuff through microscopic folds known as microchannels (Pirrone et al., 2016). The combination of endoluminal biofilms and pathogenic
secretions leaking into the lower respiratory tract via micro-channels significantly
increase the risk of VAP.
One of the key determinants in a pathogen’s etiology of VAP is the length of time
the patient has been intubated. Kalanuria et al. (2014) found that patients diagnosed with
VAP shortly after intubation were more sensitive to antibiotics. Patients diagnosed with
late-onset VAP were more difficult to treat because the causative pathogens were often
multi-drug resistant. Streptococcus Pneumonia, Hemophilus Influenza, Methicillinsensitive Staphylococcus Aureus (MSSA), Escherichia Coli and Klebsiella Pneumonia
were identified as common pathogens found in early-onset VAP (Kalanuria et al.).
Common pathogens identified for late-onset VAP include Methicillin-resistant Staph
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Aureus (MRSA), Pseudomonas Aeruginosa, and Extended-Spectrum Beta-Lactamase
(ESBL) (Kalanuria et al.).
Prevention and diagnosis of VAP remain challenging for medical professionals.
One of the challenges in diagnosing VAP is that there is no recognized diagnostic gold
standard. Bedside evaluation and chest x-ray are effective diagnostic tools but are not
definitive (Kalanuria et al., 2014). Although chest x-rays are frequently used as a
diagnostic tool for VAP, other conditions such as acute respiratory distress syndrome
(ARDS), congestive heart failure (CHF) and aspiration pneumonitis have similar
radiological appearances. The recommendation for diagnosis of VAP by the Infectious
Diseases Society of America (IDSA) and the American Thoracic Society (ATS) is to
obtain and culture tracheal aspirates or lower respiratory tract samples (Kalil et al., 2016).
The leading strategy for prevention of VAP remains VAP bundles (Hunter, 2012).
Ventilator associated pneumonia bundles are evidence-based interventions that promote a
prophylactic approach to preventing VAP by reducing the likelihood of aspirating
contaminated secretions and limiting the pulmonary colonization of bacteria. Ventilator
associated pneumonia bundles include elevation of the head of the bed, prophylaxis stress
ulcer medication, deep venous thrombosis prophylaxis, oral care with chlorhexidine and
daily sedation assessments that monitor breathing status (Kalanuria et al., 2014). In
addition to basic VAP bundles, some additional strategies to reduce VAP include
thorough oral care every 2-4 hours with chlorhexidine, frequent oropharyngeal
suctioning, inline ETT suctioning, and removal of condensation that develops throughout
the ventilator circuit (Miller et al., 2014).
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Due to the significant morbidity and mortality of VAP, the Institute for
Healthcare Improvement (IHI) created a campaign in 2005 called the 100,000 lives
campaign that included implementing VAP bundles as one of the core initiatives to
minimize adverse patient outcomes. The IHI’s goal was to save 100,000 lives in 18
months through six evidence-based clinical interventions (IHI, n.d.). During a follow up
study to the 100,000 lives campaign (2009), Bigham et al. concluded that there had been
significant reductions in VAP, length of intubation and mechanical ventilation and length
of hospital stay since the implementation of VAP bundles. As a result of the IHI’s
successful campaign to prevent incidences of medical harm and to improve patient health
outcomes, the campaign expanded its goal to 5,000,000 (IHI, n.d.). Despite the belief by
medical experts that the campaign was successful, the IHI has not been able to accurately
calculate and quantify the data (IHI, n.d.). The IHI continues to stress the need for
hospital compliance with VAP bundles (Kalanuria et al., 2014).
A new proposal that has gained traction in VAP prevention is single dose
antibiotic therapy within four hours of intubation (Kalanuria et al., 2014). While this
strategy has spurred interest, no randomized clinical trials have been completed to
support the theory that it could reduce VAP. As the research surrounding VAP advances,
the focus on prevention has grown to include strategies to minimize its morbidity,
mortality, and impact on the health care system. One key area of research regarding VAP
reduction is silver technology. Silver’s well established use as an antimicrobial and
treatment option for burns has advanced into a multitude of silver products.
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Silver Sulfadiazine and General Medical Use
One of the roles of silver in healthcare is to minimize the potential of infection
associated with medical devices. Nearly half of all nosocomial infections are caused by
hip prosthetics, vascular and urinary catheters, and ETTs (Monteiro et al., 2009). Due to
increasing rates of nosocomial infections and drug resistant bacteria, silver has seen
renewed interest and implementation within the medical field (Wan et al., 2016).
Advancements in nanotechnology and infectious disease research have shown
increasingly effective treatment for highly resistant infections, such as carbapenemresistant, by adding silver nanoparticles to antibiotic regimens (Wan et al.). The addition
of silver also allows providers to dose patients’ antibiotics more conservatively. Lower
doses of antibiotics reduce the likelihood that a patient will receive harmful or toxic doses
or antibiotics.
The antimicrobial properties of silver have been used to treat burn injuries for
more than 200 years (Marx & Barillo, 2014). Silver inhibits bacteria by binding to the
base pairs of the DNA helix (Rai et al., 2009) which prevents transcription and causes
damage to the cell membrane. Silver, in particular Nanosilver particles (NSP), have
broad antimicrobial properties against both gram negative and gram positive bacteria (Ge
et al., 2014). Nanoparticles are small clusters of atoms ranging from 1-100 nanometers
(Rai et al., 2009). Nanosilver particles can be impregnated into medical devices,
nanogels and nanolotions. Nanosilver particles are used for diagnosis, drug delivery and
treatment of infections. In addition to NSPs antibacterial qualities, silver has also been
used as an antiviral, antifungal, and anti-inflammatory (Ge et al., 2014). The key factors
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that influence the efficacy of silver particles as an antimicrobial agent include size, shape
(rods, particles, plates), and concentration (Ge et al.).
Other promising silver products besides NSPs include silver zeolite (SZ) and
products that release silver in their oxidized form (Monteiro et al., 2009). Silver ions are
very effective at inhibiting bacterial growth by inactivating the Thiol group within a
protein. The ions disrupt DNA replication by disrupting the transport chain and
uncoupling the oxidative phosphorylation leading to complications with cell permeability
(Duran et al., 2016). Silver zeolites provide a large surface area that makes ion release
much easier to control (Leyland et al., 2016). Additionally, the total amount of silver in
the zeolites is modest which makes it financially reasonable as an adjunct/form of
treatment.
Nanomedicine, including NSPs, is an important trend in modern medical
treatment. Due to its emergence as an adjunct or alternative to certain antibiotic
treatments, silver nanomedicine has drawn the interest of many scientific and infection
control specialists (Franci et al., 2015). The importance of nanotechnology and silver is
that they possess a large surface to area to volume ratio (Rai et al., 2009). The surface to
volume ratio makes nanoparticles increasingly intriguing for researchers who study
treatment modalities for microbes that are resistant to metal ions (Rai et al.). This ratio
creates an effective treatment strategy against bacteria. Released silver ions possess
significant antimicrobial properties in vivo and in vitro.
One limitation to the effectiveness of silver for use as an antimicrobial is that it
has a concentration-dependent toxicity for humans (Brandt et al., 2012). Percutaneous
absorption of silver can lead to argyria. Argyria is a local or systemic tissue deposition of
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silver (heavy metal) in organs such as the liver, spleen or kidney or nerves that can lead
to organ failure (Brandt et al.). Another limitation is microbial resistance to silver.
Several silver resistant bacteria have been identified globally throughout India, Utah, and
the United Kingdom (Duran et al., 2015). Overuse of silver nanoparticles as an
antimicrobial could lead to a new generation of microbial resistance.
Silver Coated Endotracheal Tubes (ETT) and VAP
Biofilms are antimicrobial resistant areas of bacterial colonization that proliferate
in moist areas (Monteiro et al., 2009). Biofilm leads to VAP by creating a network of
secretions and attached microorganisms capable of migrating along the ETT cuff polymer
down the inner lumen of the ETT (Fernandez, Levine, & Restrepo, 2012). Biofilms are a
target area of study for silver scientists. Fernandez et al. described why biofilm research
is critical to reducing VAP. A characteristic of biofilms that makes them amenable to
treatment with silver is that they are capable of extracting minerals and metals up to a
quantifiable absorption capacity. Factors that are used to quantify absorption capacity
and binding affinity are the size/charge ratio, the bacterial polysaccharide charge, the pH,
and the biofilm (Moneiro et al., 2009). As the biofilm absorbs the silver, its development
is inhibited.
One of the key pieces of literature and landmark studies related to silver
sulfadiazine and ETTs was The North American Silver-Coated Endotracheal Tube
(NASCENT) Randomized Trial (Kollef et al., 2008). This prospective, randomized,
single-blind trial was conducted in North America between 2002-2006 and involved 54
locations and 2,003 patients that required mechanical ventilation for a minimum of 24
hours. The primary outcome measure for the study was incidence of VAP.
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The only inclusionary criteria was that patients had be at least 18 years-old and
required intubation for at least 24 hours. Exclusionary criteria included current
participation in another study, cystic fibrosis, hemoptysis, pregnancy, silver sensitivity
and intubation within the past 30 days. Screening for the trial included 9,417 potential
participants. Screening and data collection focused on patients’ demographics, medical
history, immunocompetency and Acute Physiology and Chronic Health Evaluation
(APACHE) II. The APACHE II is a scoring system used in intensive care units (ICU)
that classifies each patient’s severity of illness. Of the 9,417 patients screened, 7,414
were deemed ineligible. Of the remaining 2,003, 71 ended up not requiring intubation
and 423 were intubated for less than 24 hours. Each patient was intubated with a high
volume-low pressure ETT. During the study, specific patient data collection included
daily chest radiographs, clinical signs of VAP, adverse events, length of stay in the ICU
and hospital, mortality, antibiotics used during bronchoalveolar lavage (BAL), oral care,
tracheal suctioning and method of nutrition delivery (Kollef et al.).
Results from the study identified a relative risk reduction in VAP of 34.2% for
patients intubated with ETTs coated with silver sulfadiazine (Kollef et al., 2008). Of the
patients intubated with the silver-coated ETT, 4.8% were diagnosed with VAP (37/766).
Patients with the uncoated-traditional ETT were diagnosed with VAP 7.5% of the time
(56/743). The findings were supported by a 95% confidence interval (CI) and a 90%
statistical power. Secondary findings by Kollef et al. included a delayed occurrence of
VAP as well as a relative risk reduction in the frequency of VAP diagnosed for patients
intubated with silver-coated ETTs for greater than 10 days. Patients with the silvercoated ETTs had a mortality rate of 30.4% (233/766) while patients intubated with
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standard ETTs had a mortality rate of 26.6% (198/743). Interestingly, there was no
statistical difference in the frequency or severity of adverse events in in either group
(Kollef et al.).
Another key piece of literature involving silver-coated ETTs is the Association
Between a Silver-Coated Endotracheal Tube and Reduced Mortality in Patients with
Ventilator-Associated Pneumonia by Afessa et al. (2010). In this retrospective study of
the NASCENT randomized trial, Afessa et al. analyzed the data from the NASCENT
study. The purpose was to identify an association between decreased mortality in
patients diagnosed with VAP when silver-coated ETTs were used compared to traditional
ETTs.
The results supported the original findings from the NASCENT study. Afessa et
al. (2010) concluded that ETTs impregnated with silver sulfadiazine not only reduced
incidences of VAP, but it also reduced mortality in patients with VAP. The mortality rate
for patients diagnosed with VAP that had silver-coated ETTs was 5 out of 37 (14%)
while the mortality rate for patients without the silver-coated ETT was 20 out of 56
(36%). The P value for the findings was 0.03. This implies a significant difference in
patient outcomes based on what type of ETT was used. The mortality rate for the
patients who did not have VAP was 228/729 (31%) for patients with the silver-coated
ETTs and 178/687 (26%) for patients without the silver-coated ETTs. Although no
significant conclusions were made regarding mortality in the group that did not develop
VAP, respiratory failure, multi-organ failure, and sepsis were most frequently cited as
their cause of death (Afessa et al.).
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Studies involving silver coated ETTs are limited. However, there have been
several in vitro and animal studies. Many of the in vitro and animal studies have shown
effective preventative strategies and antimicrobial properties with silver.
Next, the theoretical framework that guided the project will be discussed.
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Theoretical Framework
The Preferred Reporting Items for Systematic Review and Meta-Analysis
Protocols (PRISMA-P) is a data reporting system used for systematic reviews. The goal
of PRISMA is to provide both the reader and the researcher/author transparency and
consistency while evaluating data for both systematic reviews and meta analysis.
Systematic reviews and meta-analyses are considered by many to be the gold standard for
collection, interpretation, and dissemination of research in health care (Moher, Liberati,
Tetzlaff, & Altman, 2009). Systematic reviews are becoming increasingly common
throughout healthcare due to their methodological rigor (Moher et al., 2015). As of 2010,
11 new systematic reviews were published daily (Moher et al., 2015).
In 1999, before PRISMA-P, the Quality of Reporting of Meta-Analysis
(QUOROM) was developed in response to suboptimal reporting of meta-analyses (Moher
et al., 2009). The QUOROM statement was developed by an international group who
believed that prior systematic reviews and meta-analyses were of inferior quality and
poorly presented. As systematic reviews and meta-analyses became more popular, the
QUOROM statement was redesigned into PRISMA.
The Preferred Reporting Items for Systematic Review and Meta-Analysis was
originally designed in 2005 for authors who needed a consistent framework to collect and
report data from systematic reviews and meta-analysis. Improved reporting through
PRISMA helped readers with decision making and clarity to evaluate the quality of
research being presented (Moher et al., 2009). One aspect of systematic reviews that was
felt to be lacking throughout research in healthcare was clarification and consistency.
Protocols identified by PRISMA aimed to help authors clarify and identify relevant topics
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and explicitly document on their specified topics (Moher et al.). As a result, PRISMA
lead to more consistency, integrity, and accountability (Moher et al.).
The Preferred Reporting Items for Systematic Review and Meta-Analysis
incorporates a 27 item checklist to guide researchers and minimize bias in data
compilation. The checklist includes seven major headings that consist of title, abstract,
introduction, methods, results, discussion, and funding. The checklist allows researchers
to compile data in a consistent and transparent format. The Preferred Reporting Items for
Systematic Review and Meta-Analysis was used to guide the researcher through the
process of completing a thorough systematic review.
The author reviewed the 27 item checklist created by PRISMA to organize and
compile data. The organization and compilation of data provided in-depth extrapolation
of findings for the reader. For example, data gathered by the author for the results section
will inform readers of each studies characteristics, potential bias, and individual results.
The author identified limitations of each study and completed the critical appraisal
process.
The Preferred Reporting Items for Systematic Review and Meta-Analysis also
contains a flowchart (Figure 1) to aid researchers throughout their literature review
process for evaluation of research as it relates to specific topics. The flowchart provides
readers with a visual as to how the data is collected and utilized. Each phase of process
including identification, screening, eligibility, and inclusion are clearly documented for
the reader.
The critical appraisal was completed by using the tool created by the Better Value
Healthcare Ltd (BVHC) called the Critical Appraisal Skills Programme (CASP). The

15

CASP was created by a group from Oxford, England which focuses on value based
healthcare for individuals and organizations. The group, also known as the Public Health
Resource Unit, is part of the National Health Service (NHS) in England. The Critical
Appraisal Skills Programme was designed to aide professionals who desire to use
research in their professional practice. Additionally, CASP can be used to help develop
guidelines and industry policy. One key focus of CASP is to help readers better
understand and utilize scientific data/results. The BVHC provides training courses,
education and training materials, and works with healthcare providers to improve their
understanding and value related to patient care.
The Critical Appraisal Skills Programme can aide and expedite the researcher
who is compiling data during a systematic review by asking three straight-forward
questions:
1). Is the study valid?
It is important to identify if there was any bias in the study. One of the
most effective methods to identify bias in a study is to analyze the quality of the
methods used.
2). What are the results?
If the study is determined to be valid, the results may be considered.
When reviewing the results, it is imperative to identify any ambiguity in the
findings. Additionally, the results should be examined for clinical significance.
3). Are the results useful?
If the study is unbiased and the results are valid, a determination must be made
regarding the usefulness of the results. A determination must be made regarding the
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application of the findings to the author’s original question. These three questions help
researches quickly critically appraise research and make their own determination of the
studies quality.
If the study is determined to be valuable, CASP identifies an additional 10
questions that help the researcher systematically analyze each study. The first two
questions are screening questions. If the answer to both of the first questions is “yes,” the
researcher should continue with the remaining questions.
1. Did the review address a clearly focused question?
2. Did the authors look for the right type of papers?
3. Do you think all the important, relevant studies were included?
4. Did the review’s authors do enough to assess the quality of the included
studies?
5. If the results of the review have been combined, was it reasonable to do so?
6. What are the overall results of the review?
7. How precise are the results?
8. Can the results be applied to the local population?
9. Were all important outcomes considered?
10. Are the benefits worth the harms and costs?
The cross study analysis was further clarified by utilizing the Critical Appraisal
for Summaries of Evidence (CASE) worksheet for systematic reviews. This tool, created
by Foster and Shurtz in 2013, was designed to systematically assess the overall quality of
evidence presented in each study. Pertinent topics covered in the worksheets include
topic, method, content, and application to practice.
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Next, the study methods will be described.
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Method
Purpose
The purpose of this systematic review was to examine the impact of ETTs
impregnated with silver sulfadiazine on patient’s with VAP.
Inclusionary and Exclusionary Criteria
Inclusion criteria included: human subjects that are at least 18 years-old who were
intubated for a minimum of 24 hours in an ICU; all specialty care ICUs except pediatric
and neonatal; ETTs must have been coated or impregnated with silver sulfadiazine in an
intervention group with uncoated ETTs in a control group; must have been diagnosed
with VAP. Animal studies involving intubations with silver coated ETTs were also
included. Animal trials were included due to their similarities in study design and
controls that paralleled human trials. The author focused primarily on randomized
controlled trials (RCT). No limitations were set for dates of articles. Only articles
available in English were included.
Exclusionary criteria included patients with significant hemoptysis (hemoptysis
automatically places patients at high risk for aspiration and the development of
pneumonia), patients who were previously intubated within the past 30 days (they are
respiratory compromised) and patients intubated for 14 days or greater.
Data Collection Strategy
Data collection included information specific to the study design (Table 1). These
pieces of data were collected and organized using a tool to provide a clear and concise
visualization for the author when referencing key literature. Data collection also included
data that focused on study outcomes. The collection and sorting process helped guide the
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author so that studies could be quickly referenced. Breaking down the data provided the
author a clear way to compare and contrast the studies throughout the data synthesis
Table 1
Data Collection Template
Study

Site

Patient risk

Duration

Was the

Outcomes of

Design

Sample

factors

of

ETT coated

intubation?

(age,

prior to

Intubation

or

Mortality rate

number of

intubation

impregnated

for

participants

(i.e.

with silver

participants

-how they

existing

sulfadiazine

diagnosed

were

heart

or was it an

with VAP.

selected,

disease,

uncoated

human or

immunode-

ETT?

animal

ficiency,

subjects)

chronic

Limitations

obstructive
pulmonary
disease
(COPD)

The author critically analyzed the selected studies with the CASP tool for
systematic reviews. The author focused on such items as the quality of the study design,
quality of data, the relevance of the data and the implications of how the data can be
used.
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The goal of the data synthesis was to provide a method for the author to look
across the studies and determine if commonalities or variations were found throughout
the available data. The Critical Appraisal for Summaries of Evidence (CASE) worksheet
for systematic reviews was used to compare across studies. The author then examined
across all studies to identify commonalities and variances throughout the descriptive data
synthesis. It was critical to determine if the results of the studies supported or refuted
each other.
Next, the study results are presented.
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Results
Based on the inclusion and exclusion criteria, the systematic review included five

Identification

studies. The pathway that resulted in the selection of the studies is illustrated in Figure 1.

Records identified through
database searching
(n =27 )

Additional records identified
through other sources
(n =7 )

Eligibility

Screening

Records after duplicates removed
(n = 22 )

Records screened
(n =22 )

Records excluded
(n =5 )

Full-text articles assessed
for eligibility
(n = 7 )

Full-text articles excluded,
with reasons
(n =0 )

Included

Studies included in
qualitative synthesis
(n = 5 )

Studies included in
quantitative synthesis
(meta-analysis)
(n =5 )

Figure 1. The Preferred Reporting Items for Systematic Reviews and Meta-Analysis
Flow Diagram.
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The data collection tables are presented in Appendix A, with each of the five
studies individually numbered. The critical appraisal of each study is presented in
Appendix B.
The study conducted by Berra et al. (2004; Appendix A-1) was a randomized
controlled trial conducted at the National Institutes of Health Animal Research
Laboratory in Bethesda, Maryland. The authors examined whether or not ETTs coated
with antiseptics (silver) would decrease bacterial colonization of ventilator circuits, lungs,
and ETTs. Subjects were female Dorset sheep (N=16) that were intubated for 24 hours
and ranged in weight from 25-37 kg. The intervention group (n=8) were intubated with
silver-coated ETTs and the control group (n=8) were intubated with standard ETTs. Each
subject was considered to be in optimum health prior to the study. Based on laboratory
data and chest radiographs taken three days before the start of the study, no
predetermined risk factors were identified. No antibiotics had been given to the subjects
within four weeks of the study’s start.
Each subject was successfully intubated on the first attempt. Subjects were
placed in the prone position during the 24-hour mechanical ventilation period.
Throughout the study, the subjects were monitored for respiratory and hemodynamic
parameters/changes, core body temperature, arterial blood gases, and urine output.
Microbiologic sampling was conducted every eight hours and included blood samples
and a swab of the internal lumen of the ETT. Mucus and secretions gathered from the
ETT were gram-stained and analyzed with light microscopy. During the study, subjects
were afebrile and not found to have developed leukocytosis or changes in chest
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radiographs. No parenteral nutrition, IV fluid replacement, or antibiotics were
administered during the study.
Results of the study were collected from autopsy and the subject’s equipment
(ETT and ventilator circuit). Tissue samples were gathered from the trachea, larynx,
bronchi and the five lung lobes of each subject. Of the subjects with the silver-coated
ETTs (intervention group), seven out of eight were free of bacterial colonization
throughout the ETT. The subjects intubated with standard ETTs (control group) had
extensive bacterial colonization of their lower respiratory tract, ETT and ventilator
circuit. Multiple bacterial species were found in the tracheal-bronchial tree and lungs of
both groups. The bacteria were found in three out of eight in the intervention group and
seven out of eight in the control group were colonized (P=0.119).
One of the limitations to extrapolating further data from this study was that all
subjects were euthanized following the 24 hours of mechanical ventilation. Due to the
euthanization, readers can only speculate which of the subjects would have developed
VAP. While the likelihood is high that all the bacterially colonized subjects would have
developed VAP, no conclusions can be made.
This study was critically appraised using the CASP tool (Appendix B-1). The
study addressed a specific question regarding effectiveness of silver-coated ETTs and
bacterial colonization of the lungs, ETT and ventilator circuit. The study appropriately
randomized subjects and blinded staff involved with the study. Subjects were similar in
overall health at the start of the study, treatments were consistent between both the
control and intervention groups, and all were accounted for in the results. No treatment
effect was documented. Although the study participants were sheep, the results were
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comparable to those of human studies. All important outcomes were identified and
considered during the study. Although the data gathered from the study supported similar
studies, it is unclear if the harms/costs of the study were beneficial because all
participants were euthanized following the 24 hours of mechanical ventilation.
The study conducted by Berra et al. (2008; Appendix A-2) was a randomized
controlled trial that was performed on eight Dorset sheep that were mechanically
ventilated for a period of 24 hours. All study participants were deemed healthy prior to
the study. Each had undergone multiple screening tests including labs, chest radiographs
and clinical examinations. Additionally, each was intubated successfully on the first
attempt. The study was conducted in a laboratory at the National Institute of Health in
Bethesda, Maryland. Four sheep were intubated with silver-coated ETTs (intervention
group) and the remaining were intubated with standard polyurethane ETTs (control
group).
Presence of colonization was determined by taking biopsies during autopsy. A
total of 12 biopsies of 50 mg each were collected from various sites including the five
lung lobes, five lobar bronchi, 2 centimeters superior to the carina and one from the
trachea at approximately the midpoint of the ETT. Extensive colonization was found in
the lower respiratory tract (p < .01) of the sheep who were intubated with standard ETTs
as compared to those in the control group. Although the colonization was most abundant
in the lower respiratory tract, it was also present throughout the breathing circuit of the
ventilator tubing (p = 0.003) of the control group sample.
The study did have several limitations, including the small sample size of eight
participants. Another limitation of the study was that the results were presented in
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difficult to comprehend format (ex: 5.0 × 105– 4.5 × 108). Presenting results/data in this
type of format limits the audience that can utilize and interpret the results. In order to
understand and utilize the data, readers need to spend more time than expected to find
supportive data for their own use.
This study was critically appraised using the CASP tool (Appendix B-2). The
study, a randomized controlled trial, addressed the question of whether or not silvercoated ETTs could effectively prevent bacterial colonization of the respiratory tubing and
lower respiratory tract. All subjects were similar at the start of the study and accounted
for in the results. Unfortunately, it is not clear if all experimental interventions were
consistent between the control group and intervention group. Additionally, there were no
specifics reporting how the health workers were blinded during treatment/interventions.
No treatment effect was reported. Results of the study were similar to results of human
studies. However, it is not clear whether or not the results from this study can be applied
to human studies. It is unclear if all important outcomes were considered because
subjects were euthanized following the study. Euthanization prevented subjects from
fully developing VAP. It is unclear if the benefits outweigh the costs/harm caused by this
study. Euthanization and animal studies is an ethical question that can only be answered
on an individual basis.
The study conducted by Rello et al. (2006; Appendix A-3) was a single blind
randomized controlled trial that focused on whether or not reducing bacterial airway
colonization with silver-lined ETTs was effective. The study was conducted at four
hospitals. One hospital was in the United States and three were in Spain. In order to
qualify for the study, participants had to be at least 18 years old, intubated for a minimum

26

of 24 hours and be a patient in the intensive care unit (ICU). One hundred fifty-five were
screened for the study but only 121 were entered in the study. The 34 that were not
entered in the study were either intubated for less than 24 hours or not intubated at all.
The intervention group (silver-coated ETTs) consisted of 61 participants and the control
group (standard ETTs) consisted of 60 participants. The mean age was 64.6.
The authors identified significant patient risk factors that increased the likelihood
of participants developing VAP including previous intubations, recent surgery, trauma
patients, use of muscle relaxants (paralytics), continuous sedation, smoking coma, and
alcohol abuse. Nineteen participants from the intervention group and 28 from the control
group had at least one of these risk factors. Additional risk factors identified in study
included enteral nutrition, parenteral nutrition and antibiotic exposure within the previous
14 days. Of the 61 participants in the intervention group, 42 received enteral nutrition, 12
received parenteral nutrition and 32 had received antibiotics within the previous 14 days.
Of the 60 participants in the control group, 45 received enteral nutrition, 8 received
parenteral nutrition and 30 had received antibiotics within the previous 14 days.
The authors concluded that the silver-coated ETT was effective at reducing
bacteria in tracheal aspirates and increasing the time it takes for the inter-lumen of the
ETT to become colonized with bacteria. The most significant finding was delayed interlumen colonization of the silver-coated ETTs (p 0.02) compared to the standard ETTs
(3.2 days for silver ETTs vs 1.8 days for standard ETTs).
Limitations of the study included lack of “blinding” the ICU staff. The ICU staff
knew which patients had silver-coated ETTs and which had standard ETTs. This
provides a potential for bias and could have impacted how they provided oral care,
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suctioning, etc. Additionally, the infection control process was not standardized between
the four hospitals. Lack of standardization could have a significant impact on
outcomes/results.
This study was critically appraised using the CASP tool (Appendix B-3). This
single-blind study addressed whether a silver-coated ETT could feasibly and safely
reduce bacterial colonization of the lungs and tracheal aspirates. All participants who
entered the study were accounted for and all relevant clinical outcomes were reported. It
is not clear if the control group and intervention group were similar at the start of the trial
because only baseline characteristics and demographics were provided. Unfortunately,
healthcare workers were not blinded during treatments or data collection and treatment
standards varied amongst the four facilities. No treatment effect was reported. It is
unclear if the results of this trial could be applied to similar studies due to the lack of
standardization among the four facilities (potential for bias). The benefits of the Rello et
al. study outweigh the risks/costs. No adverse outcomes were reported.
The NASCENT study conducted by Kollef et al. (2008, Appendix A-4) was a
prospective, randomized, single-blind study. The study was conducted between 20022006 at 54 medical centers throughout North America. There were 9,417 patients
screened for the study and of those, 2,003 were expected to require mechanical
ventilation for at least 24 hours. Ultimately, the study involved 1,509 intubated
participants. Of those, n=766 were intubated with the silver-coated ETT (intervention
group) and n=743 were intubated with the standard ETT (control group).
Significant risk factors identified prior to the study were smoking,
immunodeficiency and Chronic Obstructive Pulmonary Disease (COPD). The number of
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study participants who smoked was 234. Of the 234 smokers, 121 were intubated with
the silver-coated ETT (intervention group) and 113 were intubated with the standard ETT
(control group). Of the 370 immune-deficient participants in the study, 184 were
intubated with the silver-coated ETT (intervention group) and 186 were intubated with
the standard ETT (control group). The number of participants who had COPD was 211.
Of the 211 with COPD, 89 were intubated with the silver-coated ETT (intervention
group) and 122 were intubated with the standard ETT (control group).
Results of the study (microbiologically confirmed cases of VAP) were a 4.8%
incidence of VAP for the participants intubated with the silver-coated ETT (n=37) and a
7.5% incidence of VAP for participants intubated with the standard ETT (n=56). These
findings had a 95% confidence rating. The findings suggest a 35.9% relative risk
reduction in the development of VAP for participants intubated with silver-coated ETTs
compared to the standard ETTs when intubated for a minimum of 24 hours. Participants
with silver-coated ETTs were found to have a substantial reduction in microbiologically
confirmed cases of VAP compared to the control group.
An additional finding was a delayed onset of VAP for participants intubated with
the silver-coated ETT compared to the standard ETT. After 10 days on intubation, only
27/766 (intervention group) had developed VAP while 50/743 (control group) had
already been diagnosed with VAP (P=0.005).
One of the limitations of this study was that it was limited to patients who could
consent for themselves. This precludes a large amount of potential participants who
required intubation such as patients in respiratory distress who require emergent
intubation or patients who have altered mental status and can’t self-consent. These
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patients are highly susceptible to the development of VAP and would have been valuable
to include in the study.
This study was critically appraised using the CASP tool (Appendix B-4). The
prospective, randomized, single-blind study clearly focused on whether or not a silvercoated ETT would reduce the incidence of microbiologically confirmed VAP. All
clinically important outcomes from the study were reported including VAP diagnosis and
onset of VAP. Participants in the study were similar at the start of the trial, treatments
throughout the trial were consistent, and all were accounted for in the results. Study
personnel were blinded to control/intervention group. The treatment effect was a 35.9%
relative risk reduction in incidence of VAP. Results from the Kollef et al. study can be
applied to the local population. The benefits outweigh the harms/costs as no adverse
outcomes were reported.
The study conducted by Afessa et al. (2010; Appendix A-5) was a retrospective
cohort analysis of patients from the NASCENT trial who had developed VAP. Afessa et
al. applied a stepwise multivariate logistic regression on the patients from the NASCENT
study (N=93) that developed VAP to determine whether or not there was a reduced
mortality rate when a silver-coated ETT was used instead of the standard ETT.
Of the 93 patients, 37 were intubated with a silver-coated ETT (intervention
group) and 56 were intubated with the standard ETT (control group). The mean age of
the intervention group was 59.8. The mean age of the control group was 63.3. There
were no significant demographic differences between the two groups.
Significant patient risk factors identified by the authors included COPD,
immunodeficiency, emergent surgery/trauma, inappropriate antibiotic administration, and
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coma. The intervention group contained five COPD patients, eight immunodeficient
patients, and three that required emergent surgery or were involved in a trauma. The
control group contained seven COPD patients, nine who were immunodeficient, six that
required emergent surgery or were involved in a trauma, nine that had received
inappropriate antibiotics and one in a coma.
Results from the retrospective cohort analysis found a mortality rate of 14% for
patients in the intervention group that developed VAP (n=5). The mortality rate for
patients in the control group that developed VAP was 36% (n=20) (p=0.03) (CI 95%).
The authors concluded that the only variable that altered mortality rate was whether
patients were in the intervention group (silver-coated ETT) or the control group (standard
ETT).
Another significant finding was a reduction in the development of multidrug
resistant bacteria for patients in the intervention group as compared to those in the control
group. Of the 37 patients in the intervention group, 13 were diagnosed with bacterial
infections that were considered multidrug resistant (approximately 35%). Of the 56
patients in the control group, 25 (45%) were diagnosed with bacterial infections that were
considered multidrug resistant. There was a 29% reduction in multidrug resistant
bacterial infections found in patients intubated with silver-coated ETTs (p=0.48).
The study had two major limitations. Foremost was the limited sample size
(N=93). A larger sample size would have strengthened the findings. The second
limitation was that the study was a retrospective study of the NASCENT study.
Retrospective studies do not prove a direct cause and effect relationship.
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This study was critically appraised using the CASP tool (Appendix B-5). This
retrospective cohort analysis of the randomized NASCENT trial addressed whether or not
there was an association between silver-coated ETTs and reduced mortality for patients
who developed VAP. No significant differences in demographics or risk factors between
the control group and the intervention group were reported prior to the study. Study
personnel were blinded to the control/intervention groups and followed antibiotic
guidelines for administration protocols. Unfortunately, it is not clear what other VAP
reduction strategies, such as ventilation strategies, VAP bundles and/or medications were
implemented during the study. No treatment effect was reported. However, group
designation was found to be a predictor of mortality with a 95% confidence interval.
All study participants were accounted for in the results. The results of the study
were consistent with similar studies throughout this systematic review. It is unclear if all
pertinent outcomes were reported during this study. The authors cite a limitation of the
inability to prove “cause and effect” between silver-coated ETTs leading to a reduction in
patient mortality rates. The benefits of this study (60% reduction in mortality rate for the
intervention group) outweigh the harms/costs.
A cross study analysis was completed with the CASE worksheets (Appendix C
and D). The cross study analysis looks across all studies to determine if there are
similarities and/or differences in the findings of each study. All five studies included in
this systematic review provided summaries that were specific to the scope of this review.
Nearly all, with the exception of the Rello et al., offered transparency to the reader. All
studies provided appropriately cited recommendations but unfortunately, the
recommendations were dated. Two studies included in this systematic review were
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completed on or prior to 2006. The most current studies were authored by Afessa et al.
(2010), Kollef et al. (2008), and Berra et al (2008). The summaries of all studies were
unbiased. The most significant study and results included in this systematic review are
from Kollef et al. (2008). Based on the large sample size and scope of the study, the
results and summary provide detailed data that allows the reader to gauge the accuracy of
the intervention (silver-coated ETT) with less potential for bias.
The most significant finding across the studies was a reduction in VAP rates for
the intervention group. Each study reported that the intervention group had either fewer
patients diagnosed with VAP, a reduction in colonization throughout the ETT/breathing
circuit/lungs, or a reduction in mortality rates for patients who were diagnosed with VAP.
Next, summary and conclusions will be presented.
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Summary and Conclusions
A systematic review was conducted to determine whether silver-coated ETTs
were effective at reducing the incidence of VAP when compared to standard ETTs. A
comprehensive literature review was conducted using CINAHL, OVID and PubMed.
The literature review focused on ventilator-associated pneumonia, ETTs, silversulfadiazine, and VAP. An abundance of literature was found pertaining to VAP and
silver-sulfadiazine individually. However, information linking these topics was limited.
After identifying inclusion and exclusion criteria and using the PRISMA
flowchart, five studies were identified. Data collection tables that identified key variables
for each of the individual studies were developed and completed. Then, each study was
critically appraised using the The Critical Appraisal Skills Programme (CASP) tool. The
Critical Appraisal Skills Programme helped determine if the study was valid, what the
results meant and if the results were useful. It was also used to screen the studies in a
structured manner so that a determination could be made regarding the validity of the
data reported within the study.
Following the critical appraisal, a cross-study analysis was completed with the
CASE worksheet. The Critical Appraisal Skills Programme was used to gauge
transparency of the study, understand the scope of the study, identify any potential bias,
and review the author’s recommendations following the results. Findings across the five
studies were also compared and contrasted.
After extensively reviewing and appraising the studies, Kollef et al. (2008).
Afessa et al. (2010) and Rello et al. (2006) provided the most relevant data for this
systematic review since these studies used human subjects and had larger sample sizes.
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Kollef et al. and Rello et al. conducted their studies at multiple sites. One methodological
problem identified from the Kollef et al. and Afessa et al. studies was a lack of
documentation regarding patient care standards. Key components of patient treatment
including frequency of antibiotics, VAP bundles, and additional preventative strategies
were not clear.
Both Berra et al. studies (2004 and 2008) provided valuable data for this
systematic review; however, these were animal studies. The results were consistent with
human studies. While the results are essential to this systematic review, the results of
animal studies do not have the same significance to researchers as human studies. One
methodological limitation to the Berra et al. studies was the absence of treatment effect
and another limitation was a question of benefit from the study. The question of benefit
stems from the fact that all subjects involved in the Berra et al. studies were euthanized at
the conclusion of the study.
All studies reported a reduction or absence of bacteria within the breathing circuit,
ETT or lungs of the subjects from the intervention group as compared to the control
group. These findings were consistent across all studies. One landmark study, Kollef et
al. (2008) not only found a 35.9% relative risk reduction in microbiologically confirmed
cases of VAP for the intervention group, but also reported that it took significantly longer
for the intervention group to develop VAP (p <.005). In addition to reduced colonization,
Afessa et al. (2010) reported a reduction in mortality rate for patients who were in the
intervention group n=5 (14%) that developed VAP compared to the control group n=20
(36%).
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There were several limitations throughout this systematic review. One of the
limitations was the number of studies available that met the inclusion criteria. Only five
were identified as appropriate based on the inclusion criteria and thus additional research
is needed. Another limitation was the age of some of the studies, including Berra et al.
performed in 2004 and Berra et al. from 2008. Although the study was not current, the
results of the study were consistent with more recent studies. One additional limitation
was the subjects in two of the studies were not human. Berra et al. (2004) and Berra et al.
(2008) studies were conducted on Dorset sheep.
In summary, the results of the studies included in this systematic review
concluded that silver-coated ETTs effectively reduce the incidence of VAP. Findings
were consistent across the studies.
Next, the recommendations and implications for advanced practice nursing will
be discussed.
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Recommendations and Implications for Advanced Nursing Practice
Ventilator-associated pneumonia is an expensive and dangerous complication of
mechanical ventilation. Ventilator-associated pneumonia prevention is a national patient
safety standard. When patients develop VAP, they require longer periods of intubation
and mechanical ventilation. Endotracheal tubes increase the risk of developing
pneumonia by suppressing innate protective airway reflexes (Miller et al., 2014). A
microbiologically confirmed case of VAP also prolongs hospital stays, increases the cost
of the hospitalization, requires increased hospital services and increases the risk of death.
As care-providers for acutely ill patients throughout the operating rooms,
intensive care units and emergency rooms, Certified Registered Nurse Anesthetists
(CRNAs) must advocate for additional strategies to prevent VAP for patients that remain
intubated following procedures. One of those strategies is using products impregnated
with silver. Silver-coated ETTs can reduce the bacterial colonization of ETTs, breathing
circuits and a patient’s lungs.
Education and training by CRNAs should focus on identifying patients preoperatively that are likely to need prolonged mechanical ventilation. These patients are at
high-risk for developing VAP. While evidence-based interventions such as elevation of
the head of the bed, prophylactic stress ulcer medication, oral care with chlorhexidine,
and prophylactic deep vein thrombus injections remain the most common interventions
used to reduce the development of VAP in the ICU, CRNAs can intervene even earlier by
identifying these patients and consulting with the surgeon to determine if post-operative
intubation is likely.
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Certified Registered Nurse Anesthetists are in a key position to advocate on
patients’ behalf for the use of silver-coated ETTs as a proactive approach to reduce the
risk of developing VAP for those who are likely to remain intubated for greater than 24
hours. By educating caregivers about the benefits of silver-coated ETTs for patients
requiring prolonged intubation following surgery, CRNAs can help improve patient
outcomes, reduce costs associated with hospital admissions, and reduce the risk of death
in patients who develop VAP.
Certified Registered Nurse Anesthetists should be involved with policy
development related to VAP, silver-coated ETTs and prevention strategies. As CRNAs,
our impact on patient care should not be limited to the OR. As master’s educated
providers of care, CRNAs are trained to review and interpret research. Interpreting and
validating study results with the assistance of tools such as PRISMA, CASP, and CASE
are foundational to policy development, which provide the framework for improvements
to patient care. Input regarding evidence-based treatment interventions and improving
patient outcomes are needed. The CRNA can also advocate for policy at the national
level via participation in professional organizations
Further research is needed to confirm the results reported in this systematic
review. Research should focus on patient outcomes following intubation with silvercoated ETTs, any adverse outcomes, and financial considerations that may occur as a
result of implementing a policy related to intubations with silver-coated ETTs for patients
requiring prolonged intubation following surgery.
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Certified Registered Nurse Anesthetists are in a unique position to advocate for
patients, educate staff about treatment strategies, and develop policy based on evidencebased practice. Due to the expanding role of CRNAs across the healthcare spectrum, it is
critical CRNAs remain current with medical research, medical innovation, and treatment
strategies.
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Appendix A
Table A-1.
Berra, L., De Marchi, L., Yu, Z. X., Laquerriere, P., Baccarelli, A., & Kolobow, T. (2004). Endotracheal tubes coated with antiseptics
decrease bacterial colonization of the ventilator circuits, lungs, and endotracheal tube. Anesthesiology: The Journal of the American
Society of Anesthesiologists, 100(6), 1446-1456.
Study Design

Site/Sample

Patient Risk
Factors Prior to
Intubation

Duration of
Intubation

Outcomes of
Intubation

Limitations

Randomizedcontrolled
study.

National
Institutes of
Health Animal
Research
Laboratory
(Bethesda,
Maryland).

No predetermined
risk factors based
on laboratory data
and chest
radiograph 3 days
prior to the study

Intubation = 24
hours with
mechanical
ventilation.

Following the study,
an autopsy was
conducted and
included tissue
samples from the
trachea, larynx,
bronchi, and the 5
lobes of the lungs.

After 24 hours of
mechanical
ventilation, subjects
were euthanized.
This prevented the
subjects from
developing
pneumonia (which
likely would have
occurred with
bacterial
colonization within
the lower
respiratory tract).

Control group:
n = 8 with
standard
uncoated ETTs.

Subjects were
Study group:
N = 16 Sheep,
n = 8 with silver female Dorset
coated ETTs
Median body
weight = 30.5kg
(range = 2537kg).
Microscopic
and

Subjects had not
received any
antibiotics for a
minimum of 4
weeks prior to the
study.

Intubation and
securement of
airway was
completed on first
attempt (without
difficulty) for all
N 16 subjects.
Respiratory and
hemodynamic
parameters, core
body temperature,
arterial blood gases,
and urinary output

Bacterial growth
within the ETT and
ventilator circuit of
the “study group”
was prevented in 7
of the 8 eight
subjects and greatly
reduced for the
eighth subject when
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microbiologic
studies were
performed by
observers who
were blinded to
each group.
Sheep placed in
prone position
to simulate
human
positioning

were monitored.
Parenteral nutrition
and fluid
replacements were
provided as needed.
Microbiologic
sampling was done
every 8 hours and
included blood
samples and a swab
of the internal lumen
of the ETT (to detect
bacterial growth).
Mucus and
secretions from the
inner lumen of the
ETTs were gramstained and analyzed
with light
microscopy
No systemic or
topical antibiotics
were used.
During the study all
subjects were free of
fever, leukocytosis,
and chest
radiographic
changes.

compared to the
control group.
Study group =
7 out of 8 were free
of bacterial
colonization
throughout the ETT.
Control group =
bacterial
colonization of the
ETT, ventilator
circuit, and lower
respiratory tract.
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Table A-2.
Berra, L., Kolobow, T., Laquerriere, P., Pitts, B., Bramati, S., Pohlmann, J., ... & Baccarelli, A. (2008). Internally coated endotracheal
tubes with silver sulfadiazine in polyurethane to prevent bacterial colonization: a clinical trial. Intensive Care Medicine, 34(6), 1030.
Study Design

Site/Sample

Patient Risk Factors Duration of
Prior to Intubation
Intubation

Results

Limitations

Randomized
Controlled Trial

LaboratoryNational Institute of
Health (Bethesda,
Maryland)

Healthy upon
enrollment based
on clinical findings,
lab values, and
chest radiographs
throughout the
intubation period

Autopsy-12 biopsy
samples (50 mg
each)
5 (1 from each lung
lobe)
5 (lobar bronchi)
1 (2cm above
carina)
1 (middle of ETT)

Study limited to 24
hours

Dorset Sheep
mechanically
ventilated

N= 8
Silver coated ETT
(n=4)
Standard ETT
(n=4)

Intubation
successful on 1st
attempt for all
participants

24 hours

Standard ETTlower respiratory
tract
(p < .01) and
ventilator tubing
extensively
colonized (p =
.003)
Silver coated ETTno colonization

8 subjects
Microscopy and
bacteriology
findings difficult
for the reader to
quantify
(example: 5.0 ×
105– 4.5 × 108)
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found on ventilator
tubing
Microscopic
findings within the
standard ETT-thick
and dense secretion
layer (50-750
micrometers thick)
and extensive
bacterial
colonization
Silver coated ETTthin mucus layer
(0-450 micrometers
thick) and no
bacterial
colonization
Presence of bacteria
within ETT
Standard ETT 3 out
of 4
Silver coated ETT 0
out of 4
(p = 0.14)
P values calculated using Wilcoxon-Mann-Whitney and Fisher’s exact test
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Table A- 3.
Rello, J., Kollef, M., Diaz, E., Sandiumenge, A., del Castillo, Y., Corbella, X., & Zachskorn, R. (2006). Reduced burden of bacterial
airway colonization with a novel silver-coated endotracheal tube in a randomized multiple-center feasibility study. Critical Care
Medicine, 34(11), 2766-2772.
Study Design

Site/Sample

Patient risk factors
prior to intubation

Duration of
Intubation

Results

Limitations

Randomized
Controlled Trial
utilizing allocation
concealment

ICU patients 18
years and older
(mean age 64.6)

Antibiotic exposure
within past 14 days
RIC (Respiratory
Infection Control)
Silver ETT= 32
Standard ETT = 30

Minimum of 24
hours

Silver device had
delayed microbial
colonization
compared to
standard ETT
(p .02)

No “blinding” of
outcome
assessment
(potential for
detection bias)

N = 155
Single blind study
34 excluded (6 not
intubated and 28
intubated less than
24 hours)
121 intubated for
minimum 24 hours
61 with silver
coated ETT/60 with
standard ETT

Risk factors for
VAP during
previous 30 days
include previous
intubations,
surgery, trauma,
use of muscle
relaxants,
continuous
sedation, smoking,

Silver ETT had
bacterial burden
found in tracheal
aspirates
Silver tube showed
delayed inter-lumen
colonization 1.8
days for RIC device
compared to 3.2

No blinding of
participants and
personnel (potential
for performance
bias)
ICU staff may have
bias due to inability
to “blind” them as
the ETTs are
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4 Hospitals-1 in the
United States
(n = 56) and 3 in
Spain (n = 99)

coma, alcohol
abuse (p .09)
Silver ETT = 19
Standard ETT = 28
Enteral nutrition
Silver ETT = 42
Standard ETT = 45
Parenteral nutrition
Silver ETT = 12
Standard ETT = 8

days for standard
ETT
(p .02)

different in
appearance
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Table A-4.
Kollef, M. H., Afessa, B., Anzueto, A., Veremakis, C., Kerr, K. M., Margolis, B. D., ... & Restrepo, M. I. (2008). Silver-coated
endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial. JAMA, 300(7), 805-813.
Study Design

Site/Sample

Risk factors prior to
intubation

Duration of
Intubation

Results

Limitations

A prospective,
randomized,
single-blind
controlled
study.

Fifty-four medical
centers throughout
North America
between 20022006.

Smoker (n = 121 with
silver-coated ETT;
n = 113 with standard
ETT).

> n 24 hours.

With a 95% confidence
rating, n = 37 patients
with the silver-coated
ETT were diagnosed with
microbiologically
confirmed cases of VAP
(4.8%).

Only patients able
to consent were
included in the
study. This
prevented patients
who required
emergent
intubations, those
with a change in
mental status, and
other high risk
patients from
participating in the
study. These
patients are highly
susceptible to
developing VAP.

Each site was
given
numbered
envelopes that
contained a
randomization
card for each
study
participant.
Microbiology
lab personnel
and study
investigators
were blinded

9417 patients were
screened for the
study.
N = 2003 patients
that were expected
to require
mechanical
ventilation for
greater than 24
hours were
identified and
randomized for the
study.

Immunodeficiency (n =
184 patients who had the
silver-coated ETT and
n = 186 who had the
standard ETT).
COPD (n = 89 patients
that had the silver-coated
ETT and n = 122 patients
that had the standard
ETT)

n = 56 patients with
standard ETT were
diagnosed with
microbiologically
confirmed cases of VAP
(7.5%).
Findings suggest a 35.9%
relative risk reduction in
the development of VAP
for patients intubated
greater than 24 hours.

51

to group
data/specifics.

n = 766 with
silver-coated ETT.
n = 743 with
standard ETT.
Human subjects
were used for this
study.

Patients with silver-coated
ETT had substantial
reduction in diagnosed
cases of VAP.
Patients with silver-coated
ETT took longer to
develop VAP (10 days)
n = 27/766 than patients
who had the standard ETT
n = 50/743 (P = 0.005)
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Table A-5.
Afessa, B., Shorr, A. F., Anzueto, A. R., Craven, D. E., Schinner, R., & Kollef, M. H. (2010). Association between a silver-coated
endotracheal tube and reduced mortality in patients with ventilator-associated pneumonia. CHEST Journal, 137(5), 1015-1021.
Study Design

Site/Sample

Retrospective
cohort
analysis for
patients who
developed
VAP in
NASCENT
study
(N 93)

N 93 with
Silver ETT
microbiologically COPD = 5
confirmed VAP
Immunodeficiency = 8
Emergency surgery/trauma = 3
Silver ETT n =
Inappropriate antibiotics = 6
37
Coma = 0
Mean age 59.8
Standard ETT
Standard ETT
COPD = 7
n = 56
Immunodeficiency = 9
Mean age 63.3
Emergency surgery/trauma = 6
Inappropriate antibiotics = 9
No significant
Coma = 1
demographic
differences
between groups

Stepwise
multivariate
logistic
regression

Patient risk factors prior to
intubation

Duration of
Intubation

Results

Limitations

Greater than
24 hours

Mortality rate for
VAP patients
with silver ETT
14% (n =5)

Retrospective studies
do not prove a cause
and effect relationship
(silver vs standard
ETT)

Mortality rate for
VAP with
Small sample size (N
standard ETT
93)
36% (n=20)
P = 0.03
Only variable
that altered
mortality rate
was treatment
group (silver
ETT vs standard
ETT) 95% CI
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Silver ETT = 13
developed
potentially
multidrug
resistant bacteria
Control group =
25 developed
potentially
multidrug
resistant bacteria
(P = 0.48)
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Appendix B
Critical Appraisal Skills Programme (CASP) Tables
Table B-1.
Berra, L., De Marchi, L., Yu, Z. X., Laquerriere, P., Baccarelli, A., & Kolobow, T.
(2004). Endotracheal tubes coated with antiseptics decrease bacterial colonization of the
ventilator circuits, lungs, and endotracheal tube. Anesthesiology: The Journal of the
American Society of Anesthesiologists, 100(6), 1446-1456.

Question

Yes

Can’t No
Tell

1) Did the review address a clearly focused question?

X

Yes. The study focused on bacterial colonization of the
lungs, ETT, and ventilator circuit when an ETT coated with
silver-sulfadiazine was used.
2) Was the assignment of patients to treatments
randomized?
Yes. The authors conducted a controlled-randomized study
of female Dorset sheep (N=16). The sheep were separated
into two groups. The control group was intubated with a
standard ETT (n=8) and the intervention group was intubated
with a silver-coated ETT (n=8). The study was conducted at
the National Institutes of Health Animal Research Laboratory
in Bethesda, Maryland.

X
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3) Were patients, health workers, and study personnel

X

blinded?
Yes. All microbiologic and microscopic studies were
completed by blinded personnel.
4) Were the groups similar at the start of the trial?

X

Yes. Based on laboratory data and chest radiographs three
days prior to the study, no predetermined risk factors were
identified in either group. Patients had not received any
antibiotics for a minimum of four weeks prior to the study.
5) Aside from the experimental intervention, were the

X

groups treated equally?
Yes. All were induced with 7mg/kg Ketamine and
maintained on Sodium Pentobarbital/Pancuronium.
Ventilator settings were comparable for both groups. Patient
monitoring consisted of respiratory and hemodynamics,
temperature, blood gas analysis, urine output, blood cell
counts, and chest radiographs. Parenteral nutrition and fluid
replacement were given as needed to both groups.
Patients were placed in prone position. No antibiotics were
administered during the study for either group.
6) Were all the patients who entered the trial properly
accounted for at its conclusion?

X
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Yes. All 16 Dorset sheep were accounted for and included in
the data/results. The results from the control group (n=8) and
the intervention group (n=8) were gathered through autopsy.
Twelve tissue samples weighing approximately 50mg each
were gathered from the trachea, larynx, bronchi, and the five
lung lobes.
7) How large was the treatment effect?

X

Treatment effect was not reported.
8) How precise was the estimate of the treatment effect?

X

Although treatment effect was not included, other findings
were very precise. The intervention group demonstrated
elimination/reduction of bacterial colonization within the
silver-sulfadiazine ETTs and near prevention of bacterial
colonization of the lung for the intervention group. After 24
hours of intubation, the inner-lumen of the intervention
groups’ ETT was free of bacterial colonization in seven of
the sheep (P < 0.0001).
9) Can the results be applied in your context or to the
local population?
Can’t tell. The data and primary outcome provide
comparable results to other studies included throughout this
systematic review. However, because the subjects are not
humans, the results are less valued than human studies.

X
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10) Were all clinically important outcomes considered?

X

Yes. The outcomes assessed throughout this systematic
review were addressed in this study. However, because the
subjects were euthanized immediately following 24 hours of
intubation and mechanical ventilation, they did not develop
pneumonia. The only data generated from the study is
specific to bacterial colonization of the ventilator circuit,
ETTs, and lungs.
11) Are the benefits worth the harms and costs?
Can’t tell. The data/results provide a foundation for future
research. However, the euthanization of the 16 Dorset sheep
following the study may be ethically unacceptable to certain
populations.

X
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Table B-2.
Berra, L., Kolobow, T., Laquerriere, P., Pitts, B., Bramati, S., Pohlmann, J., ... &
Baccarelli, A. (2008). Internally coated endotracheal tubes with silver sulfadiazine in
polyurethane to prevent bacterial colonization: a clinical trial. Intensive Care
Medicine, 34(6), 1030.

Question

Yes

Can’t No
Tell

1) Did the review address a clearly focused question?

X

Yes. The review addressed whether or not silver-coated
ETTs could effectively prevent bacterial colonization of the
respiratory tubing and lower respiratory tract.
2) Was the assignment of patients to treatments

X

randomized?
Yes. The study was a randomized controlled trial conducted
in a laboratory at the National Institute of Health. The
subjects were female Dorset sheep (N=8). Four subjects
were given the standard ETT (n=4) and the remaining were
part of the intervention group (n=4).
3) Were patients, health workers, and study personnel
blinded?
Can’t tell. There is no documentation about the process of
data/sample collections.

X
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4) Were the groups similar at the start of the trial?

X

Yes. All subjects were healthy upon enrollment in the study
based on lab values, clinical findings, and chest X-rays.
During the 24-hour study, no fevers, purulent drainage from
the ETTs, abnormalities on chest X-ray, or leukocytosis was
found.
5) Aside from the experimental intervention, were the

X

groups treated equally?
Can’t tell. The trail does not provide specifics regarding
standardization of treatment throughout the 24-hour study.
One documented detail of significance was that all subjects
were successfully intubated on the first attempt.
6) Were all the patients who entered the trial properly

X

accounted for at its conclusion?
Yes. All were accounted for.

7) How large was the treatment effect?

X

No treatment effect was reported.
8) How precise was the estimate of the treatment effect?
No treatment effect was reported. However, the silver-coated
ETTs significantly reduced bacterial colonization within the
ventilator tubing and lower respiratory tract of the
intervention group compared to the control group.

X
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Additionally, no bacteria were found within the lumen of the
silver-coated ETTs while three of the standard ETTs were
found to have bacterial colonization. Subjects with standard
ETTs were found to have colonization of the lower
respiratory tract and the ventilator tubing was extensively
colonized.
9) Can the results be applied in your context or to the

X

local population?
Can’t tell. The data and results align with comparable studies
used for this systematic review. However, the subjects are
non-human so the results are less valuable than similar
studies that used human subjects.
10) Were all clinically important outcomes considered?

X

Can’t tell. The main outcome was identified and answered
by the authors. However, the subjects were euthanized
following the study which eliminated the possibility of
developing VAP. While the authors were able to present data
showing a reduction in colonization, the study stops short of
showing a reduction in VAP development with the use of
silver-coated ETTs.
11) Are the benefits worth the harms and costs?
Can’t tell. The study, conducted and approved by the
National Institutes of Health, does provide useful data for

X
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future researchers regarding antimicrobial effects of silvercoated ETTs. However, healthy animal subjects were used
for this study and ultimately euthanized. The ethicality of
animal research is an individual decision.
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Table B-3
Rello, J., Kollef, M., Diaz, E., Sandiumenge, A., del Castillo, Y., Corbella, X., &
Zachskorn, R. (2006). Reduced burden of bacterial airway colonization with a novel
silver-coated endotracheal tube in a randomized multiple-center feasibility study. Critical
Care Medicine, 34(11), 2766-2772.

Question

Yes

Can’t No
Tell

1) Did the review address a clearly focused question?

X

Yes. The question the study addressed was whether a silvercoated ETT could feasibly and safely reduce bacterial
colonization of the lungs and tracheal aspirates. The study
focused on ICU patients that were intubated for a minimum
of 24 hours. The results suggested the silver-coated ETT
offered delayed microbial colonization compared to standard
ETT (P .02). Additionally, the silver-coated ETT showed
delayed inter-lumen colonization-1.8 days for silver-coated
ETT compared to 3.2 days for standard ETT (P .02).
2) Was the assignment of patients to treatments
randomized?
Yes. Patients were assigned to a block-randomization list by
validated software. The study was a prospective, randomized
controlled trial that utilized allocation concealment. The

X
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study was a single blind study conducted at four hospitals,
three in Spain and one in the United States. N= 155. Of the
155, 121 were intubated for a minimum of 24 hours.
3) Were patients, health workers, and study personnel

X

blinded?
No. Both the microbiological lab personnel and the
investigators were blinded. Investigators were blinded to
block length and the microbiology lab was blinded to the
control/intervention groups. However, the ICU staff may
have been biased due to inability to “blind” them as the ETTs
were slightly different in appearance (silver-coating).
Additionally, there was no “blinding” of outcome assessment
which could have lead to potential detection bias.
4) Were the groups similar at the start of the trial?
Can’t tell. Baseline characteristics and demographics were
similar in both groups. All patients were free of respiratory
infections, bronchiectasis, hematemesis, hemoptysis, cystic
fibrosis, immunosuppression, and exhibited no allergy to
silver compounds. All patients/legally authorized
representative were required to sign an informed consent
prior to beginning the study. However, the indication for
intubation was not consistent for all patients and could
impact patient prognosis/study outcomes.

X
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5) Aside from the experimental intervention, were the

X

groups treated equally?
No. The process of infection control throughout the study
was not standardized between hospitals. Additionally, the
process of quantifying ETT colonization was different in
Spain (semi-quantitative) than it was in the United States
(quantitative). Both groups were intubated with high
volume/low pressure ETTs ranging in size from 7-9mm
internal diameters. The only difference between the ETTs
used for the groups was that the intervention groups’ ETT
was coated with silver. Each group had daily swab cultures
from the inner lumen. Tracheal colonization was gathered
and cultured by sterile suction catheters.
6) Were all the patients who entered the trial properly

X

accounted for at its conclusion?
Yes. The intervention group (n=61) and the control group
(n=60) were accounted for in the results.
7) How large was the treatment effect?

X

No treatment effect was reported.
8) How precise was the estimate of the treatment effect?
Can’t tell. No treatment effect was documented. However,
the intervention group had delayed microbial colonization
within the ETT. Other significant outcomes identified were

X
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reduced bacterial burden found in the tracheal aspirates of the
intervention group as well as delayed inter-lumen
colonization (P. 02). The outcomes were measured using
multiple measuring tools (Wilcoxon-Mann-Whitney for
between group differences and Fisher’s Exact for between
group differences in colonization).
9) Can the results be applied in your context or to the

X

local population?
Can’t tell. The results of this study are relevant for this
systematic review. However, without greater standardization
of infection control practices throughout all hospitals studied,
the potential for bias is significant.
10) Were all clinically important outcomes considered?

X

Yes. All clinically important outcomes were reported. The
study addressed whether or not silver-coated ETTs could
delay microbial colonization of the lungs, tracheal aspirate,
and inter-lumen of the ETT (reduction in airway bacterial
burden).
11) Are the benefits worth the harms and costs?
Yes. No adverse outcomes were reported during the study.
Patients in the intervention group had a reduction in bacterial
airway colonization.
Table B-4.

X
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Kollef, M. H., Afessa, B., Anzueto, A., Veremakis, C., Kerr, K. M., Margolis, B. D., ... &
Restrepo, M. I. (2008). Silver-coated endotracheal tubes and incidence of ventilatorassociated pneumonia: the NASCENT randomized trial. JAMA, 300(7), 805-813.

Question

Yes

Can’t No
Tell

1) Did the review address a clearly focused question?

X

Yes. The trial addressed the question of whether or not a
silver-coated ETT would reduce the incidence of
microbiologically confirmed VAP.
2) Was the assignment of patients to treatments
randomized?
Yes. The trial was a prospective, randomized, single-blind
controlled study. The study was conducted at 54 medical
centers throughout North America. Each medical center’s
institutional review board approved the study. Screening for
the trial involved 9417 patients. Of the 9417, 7414 were
excluded because they were either unable to consent or were
unlikely to require more than 24 hours of mechanical
ventilation. N=2003 were randomized and expected to
require intubation and mechanical ventilation for a minimum
of 24 hours. Groups were randomly selected (control vs

X
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intervention) by validated software. The control group
contained n=743. The intervention group contained n=766.
3) Were patients, health workers, and study personnel

X

blinded?
Yes. All microbiology lab personnel and study investigators
were blinded to the control/intervention groups as well as the
data and specifics related to their hospitalization.
4) Were the groups similar at the start of the trial?

X

Yes. All participants of the study were at least 18 years old.
Mean age of the intervention group was 60.9. Mean age of
the control group was 62. Exclusions included current
enrollment in another study that could conflict with this one,
cystic fibrosis, pregnancy, previous intubation within the past
30 days, severe hemoptysis, and sensitivity to silver products.
Both groups had similar patient co-morbidities including
COPD, smoking, emergent surgery, trauma, and
immunodeficiency.
5) Aside from the experimental intervention, were the
groups treated equally?
Can’t tell. The study does not detail specifics regarding
patient care. The study does detail specific patient data that
was collected such as BAL via tracheal suctioning, oral care,
daily chest radiographs, vital signs, and clinical signs of

X
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VAP. However, no specifics are provided regarding patient
treatment.
6) Were all the patients who entered the trial properly

X

accounted for at its conclusion?
Yes. There were 2,003 that were entered and eligible to be in
the study. 494 were excluded because they were either not
intubated or intubated for less than 24 hours. The remaining
1,509 are accounted for.
7) How large was the treatment effect?

X

The treatment effect (silver-coated ETTs) reported a 35.9%
relative risk reduction in the incidence of VAP. Additionally,
patients with silver-coated ETTs took longer to develop VAP
(10 days) n = 27/766 than patients who had the standard ETT
n = 50/743.
8) How precise was the estimate of the treatment effect?

X

The treatment effect, reported as microbiologically
confirmed cases of VAP, was 4.8% (37/766) for the
intervention group and 7.5% (56/743). Microbiologically
confirmed cases of VAP for the control group was 7.5%
(56/743).
9) Can the results be applied in your context or to the
local population?

X
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Yes. The trial concluded that silver-coated ETTs offered
significant reductions in both the incidence of VAP and
delayed the onset of a VAP diagnosis when compared to
standard ETTs.
10) Were all clinically important outcomes considered?

X

Yes. All the pertinent clinical outcomes from this trial were
reported. The main outcome (diagnosis of VAP) and onset
were identified and clearly stated. Demographics and
baseline characteristics for both the control group and the
intervention group were presented in table format-making it
easy for the reader to visualize and interpret.
11) Are the benefits worth the harms and costs?
Yes. No adverse outcomes were reported from the trial. The
benefits exceed the harms and costs of the trial.

X
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Table B-5.
Afessa, B., Shorr, A. F., Anzueto, A. R., Craven, D. E., Schinner, R., & Kollef, M. H.
(2010). Association between a silver-coated endotracheal tube and reduced mortality in
patients with ventilator-associated pneumonia. CHEST Journal, 137(5), 1015-1021.

Question

Yes

Can’t No
Tell

1) Did the review address a clearly focused question?

X

Yes. The review questioned whether or not there was an
association between silver-coated ETTs and reduced
mortality for patients who developed VAP. Mortality was
reduced in VAP patients from 20/56 (36%) in control group)
to 5/37 (14%) in the intervention group) N=93.
2) Was the assignment of patients to treatments

X

randomized?
Yes. This was a retrospective cohort analysis or the
NASCENT study (patients were randomized for the
NASCENT study).
3) Were patients, health workers, and study personnel
blinded?
Yes. The authors who assessed the appropriateness of
treatment and antibiotics were blinded to the treatment

X
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groups. Additionally, they followed antibiotic guidelines for
empirical antibiotic therapy for VAP patients.
4) Were the groups similar at the start of the trial?

X

Yes. There were no statistically significant differences in
demographics or risk factors between the control group and
intervention group. Each group had approximately the same
percentage of patients with pre-existing conditions such as
COPD, immunodeficiency, trauma, emergent surgeries,
inappropriate administration of antibiotics, and coma.
5) Aside from the experimental intervention, were the

X

groups treated equally?
Can’t tell. There are not details on frequency of antibiotics,
VAP bundles, types of medications given during intubation
and ventilation, or preventative strategies.
6) Were all the patients who entered the trial properly

X

accounted for at its conclusion?
Yes. There were N=93 patients identified and studied during
this retrospective cohort analysis. The control group
included 56 and the intervention group 37.
7) How large was the treatment effect?
There was no specific mention of the treatment effect.
However, group designation was a predictor of mortality and

X
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silver-coated ETTs were associated with reduced mortality
rates for patients with VAP.
8) How precise was the estimate of the treatment effect?

X

The predictor of mortality given by an odds ratio was 95%
confidence interval when comparing silver-coated ETTs to
standard ETTs.
9) Can the results be applied in your context or to the

X

local population?
Yes. These results directly apply to this systematic review.
The results are derived from the “hallmark study” in this
research, the NASCENT study.
10) Were all clinically important outcomes considered?

X

Can’t tell. While mortality was the primary outcome
identified throughout the study, the authors cite limitations
within their study by not presenting any proof of “cause and
effect” with the silver-coated ETTs and reduced patient
mortality. There may have been unidentified risk factors
(cause) that contributed to the pathophysiologic demise
(effect) of patients in one or both groups (control and
intervention).
11) Are the benefits worth the harms and costs?
Yes. Only patients able to consent were included for this
study. In the absence of this research, all of these patients

X
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would have been intubated with standard ETTs. This study
identified a 60% reduction in the mortality rate for patients
with silver-coated ETTs who developed VAP compared to
the standard ETTs (control group).
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Appendix C
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
for Individual Studies
Table C-1.
Berra, L., De Marchi, L., Yu, Z. X., Laquerriere, P., Baccarelli, A., & Kolobow, T.
(2004). Endotracheal tubes coated with antiseptics decrease bacterial colonization of the
ventilator circuits, lungs, and endotracheal tube. Anesthesiology: The Journal of the
American Society of Anesthesiologists, 100(6), 1446-1456.
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Questions
Evaluation
Summary Topic
Is the summary specific in scope and
Yes
application?
Summary Methods
Is the authorship of the summary
Yes
transparent?
Are the reviewer(s)/editor(s) of the
Yes
summary transparent?
Are the research methods transparent and
Yes
comprehensive?
Is the evidence grading system transparent Yes
and translatable?
Summary Content
Are the recommendations clear?
Not completely
Are the recommendations appropriately
cited?
Are the recommendations current?
Is the summary unbiased?
Summary Application
Can this summary be applied to your
patient(s)?

Yes
No
Yes
No
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Table C-2.
Berra, L., Kolobow, T., Laquerriere, P., Pitts, B., Bramati, S., Pohlmann, J., ... &
Baccarelli, A. (2008). Internally coated endotracheal tubes with silver sulfadiazine in
polyurethane to prevent bacterial colonization: a clinical trial. Intensive Care
Medicine, 34(6), 1030.
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Questions
Evaluation
Summary Topic
Is the summary specific in scope and
Yes
application?
Summary Methods
Is the authorship of the summary
Yes
transparent?
Are the reviewer(s)/editor(s) of the
Yes
summary transparent?
Are the research methods transparent and
Yes
comprehensive?
Is the evidence grading system transparent Yes
and translatable?
Summary Content
Are the recommendations clear?
Yes
Are the recommendations appropriately
cited?
Are the recommendations current?
Is the summary unbiased?
Summary Application
Can this summary be applied to your
patient(s)?
.

Yes
Not completely
Yes
Not completely
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Table C-3.
Rello, J., Kollef, M., Diaz, E., Sandiumenge, A., del Castillo, Y., Corbella, X., &
Zachskorn, R. (2006). Reduced burden of bacterial airway colonization with a novel
silver-coated endotracheal tube in a randomized multiple-center feasibility study. Critical
Care Medicine, 34(11), 2766-2772
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Questions
Evaluation
Summary Topic
Is the summary specific in scope and
Yes
application?
Summary Methods
Is the authorship of the summary
Yes
transparent?
Are the reviewer(s)/editor(s) of the
Not completely
summary transparent?
Are the research methods transparent and
Not completely
comprehensive?
Is the evidence grading system transparent Yes
and translatable?
Summary Content
Are the recommendations clear?
Yes
Are the recommendations appropriately
cited?
Are the recommendations current?
Is the summary unbiased?
Summary Application
Can this summary be applied to your
patient(s)?

Yes
No
Yes
Not completely
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Table C-4.
Kollef, M. H., Afessa, B., Anzueto, A., Veremakis, C., Kerr, K. M., Margolis, B. D., ... &
Restrepo, M. I. (2008). Silver-coated endotracheal tubes and incidence of ventilatorassociated pneumonia: the NASCENT randomized trial. JAMA, 300(7), 805-813.
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Questions
Evaluation
Summary Topic
Is the summary specific in scope and
Yes
application?
Summary Methods
Is the authorship of the summary
Yes
transparent?
Are the reviewer(s)/editor(s) of the
Yes
summary transparent?
Are the research methods transparent and
Not completely
comprehensive?
Is the evidence grading system transparent Not completely
and translatable?
Summary Content
Are the recommendations clear?
Yes
Are the recommendations appropriately
Yes
cited?
Are the recommendations current?
Not completely
Is the summary unbiased?
Yes
Summary Application
Can this summary be applied to your
Yes
patient(s)?

78

Table C-5
Afessa, B., Shorr, A. F., Anzueto, A. R., Craven, D. E., Schinner, R., & Kollef, M. H.
(2010). Association between a silver-coated endotracheal tube and reduced mortality in
patients with ventilator-associated pneumonia. CHEST Journal, 137(5), 1015-1021.
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
Questions
Evaluation
Summary Topic
Is the summary specific in scope and
Yes
application?
Summary Methods
Is the authorship of the summary
Yes
transparent?
Are the reviewer(s)/editor(s) of the
Yes
summary transparent?
Are the research methods transparent and
Yes
comprehensive?
Is the evidence grading system transparent No
and translatable?
Summary Content
Are the recommendations clear?
Yes
Are the recommendations appropriately
cited?
Are the recommendations current?
Is the summary unbiased?
Summary Application
Can this summary be applied to your
patient(s)?

Yes
Yes
Yes
No
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Appendix D
Critical Appraisal for Summaries of Evidence (CASE) Worksheet
for Cross Study Analysis

Critical Appraisal for Summaries of Evidence (CASE) Worksheet *Numbers in
evaluation correspond with those assigned to articles in data extrapolation chart*
Questions
Evaluation
Summary Topic
Is the summary specific in scope and
Yes- 1, 2, 3, 4, 5
application?
Not completelyNoSummary Methods
Is the authorship of the summary
Yes- 1, 2, 3, 4, 5
transparent?
Not completelyNoAre the reviewer(s)/editor(s) of the
Yes- 1, 2, 4, 5
summary transparent?
Not completely- 3
NoAre the research methods transparent and
Yes- 1, 2, 5
comprehensive?
Not completely- 3, 4
NoIs the evidence grading system transparent Yes- 1, 2, 3
and translatable?
Not completely- 4
No- 5
Summary Content
Are the recommendations clear?
Yes- 2, 3, 4, 5
Not completely-1
NoAre the recommendations appropriately
Yes- 1, 2, 3, 4, 5
cited?
Not completelyNoAre the recommendations current?
Yes- 5
Not completely- 2, 4
No- 1, 3
Is the summary unbiased?
Yes- 1, 2, 3, 4, 5
Not completely
No
Summary Application
Can this summary be applied to your
Yes- 4
patient(s)?
Not completely- 2, 3
No- 1, 5

